Biomedical Engineering Reference
In-Depth Information
957. Barkai G, Abruzova S, Berkenstadt M, Heifetz S, Cuckle H. 2003. Frequency of Down
syndrome and neural-tube defects in the same family. Lancet 361: 1331-1335.
958. Pei L, Zhu H, Ren A, Li Z, Hao L, Finnell RH, Li Z. 2005. Reduced folate carrier gene
is a risk factor for neural tube defects in a Chinese population. Birth Defects Res A Clin
Mol Teratol 73: 430-433. Abstract only.
959. O'Leary VB, Pangilinan F, Cox C, Parle-McDermott A, Conley M, Molloy AM, Kirke
PN, Mills JL, Brody LC, Scott JM. 2006. Reduced folate carrier polymorphisms and
neural tube defect risk. Mol Genet Metab 87: 364-369.
960. Yates Z, Lucock M. 2005. G80A reduced folate carrier SNP modulates cellular uptake
of folate and affords protection against thrombosis via a non homocysteine related
mechanism. Life Sci 77: 2735-2742.
961. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara
H, Tanigawara Y, Takahashi T, Kosaki K. 2006. Effects of methylentetrahydrofolate re-
ductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced
toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol
Oncol 28: 64-68.
962. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. 2005. Polymorphisms
in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of
colon cancer. Cancer Epidemiol Biomark Prev 14(11 Pt 1): 2509-2516.
963. Zhao R, Gao F, Goldman ID. 2002. Reduced folate carrier transports thiamine monophos-
phate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol
Cell Physiol 282: C1512-C1517.
964. Rothem L, Berman B, Stark M, Jansen G, Assaraf YG. 2005. The reduced folate
carrier gene is a novel selectable marker for recombinant protein overexpression. Mol
Pharmacol 68: 616-624.
965. Wright JE, Yurasek GK, Chen YN, Rosowsky A. 2003. Further studies on the interaction
of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the
reduced folate carrier as determinants of in vitro antitumor activity. Biochem Pharmacol
65: 1427-1433.
966. Jackman AL, Boyle FT, Harrap KR. 1996. Tomudex (ZD1694): from concept to care, a
programme in rational drug discovery. Invest New Drugs 14: 305-316.
967. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. 2006. The inverse
relationship between reduced folate carrier function and pemetrexed activity in a human
colon cancer cell line. Mol Cancer Ther 5:438-449.
968. Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, Asseraf
YG, Dijkmans BAC. 2004. Sulfasalazine is a potent inhibitor of the reduced folate
carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Arthritis Rheum 50: 2130-2139.
969. Assaraf YG, Sierra EE, Babani S, Goldman ID. 1999. Inhibitory effects of prostaglandin
A1 on membrane transport of folates mediated by both the reduced folate carrier and
ATP-driven exporters. Biochem Pharmacol 58: 1321-1327.
970. Naggar H, Ola MS, Moore P, Huang W, Bridges CC, Ganapathy V, Smith SB. 2002.
Downregulation of reduced-folate transporter by glucose in cultured RPE cells and in
RPE of diabetic mice. Invest Ophthalmol Vis Sci 43: 556-563.
971. Smith SB, Huang W, Chancy C, Ganapathy V. 1999. Regulation of the reduced-folate
transporter by nitric oxide in cultured human retinal pigment epithelial cells. Biochem
Biophys Res Commun 257: 279-283.
Search WWH ::
Custom Search